ABPI names Novartis’ Haseeb Ahmad as new President
The Association of the British Pharmaceutical Industry (ABPI) has revealed the appointment of a new President: Haseeb Ahmad will assume the role with immediate effect.
He steps up from his current position of Managing Director, UK, Ireland & Nordics Novartis Pharmaceuticals and Country President at Novartis UK, to manage and oversee the organisation, its board and its Code of Practice, which is administered by the Prescription Medicines Code of Practice Authority (PMCPA). He fills the vacancy left by Erik Nordkamp.
In his role, Ahmad will “take advantage of the opportunities presented by science, technology and data to help get new medicines to patients faster”, by promoting innovation and collaboration with the NHS and the UK Government.
“We are in a golden era of medicines discovery, where innovative science is converging with a data and digital revolution. These forces are coming together to treat and potentially cure diseases on a scale the likes of which we’ve not seen before,” said Ahamad. “The pharmaceutical industry, Government and the NHS must work together to ensure that patients can access innovative therapies and that we deliver the kind of healthcare that all of us in the UK deserve.”
Additionally, the organisation announced that Hugo Fry, Managing Director at Sanofi UK, has also been appointed as its Vice President. He commented on his appointment: “The UK is currently a hotbed for medical innovation, with discoveries that have a huge impact for people and patients all across the world. In the current Brexit environment it is more important than ever to collaborate across government, businesses and academia to ensure that the UK can maintain its position as a leader in world class research and development.”
Welcoming the appointments, Mike Thompson, Chief Executive of the ABPI, remarked: “I am delighted to welcome both Haseeb and Hugo to their new respective new roles. They bring a wealth of experience to the ABPI, which will be invaluable as we look to make the most of the challenges and opportunities facing our sector.”
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …